[1]陈孝辉.哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病的临床效果[J].医学信息,2022,35(13):97-99.[doi:10.3969/j.issn.1006-1959.2022.13.021]
　CHEN Xiao-hui.Clinical Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Ambroxol in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(13):97-99.[doi:10.3969/j.issn.1006-1959.2022.13.021]
点击复制

哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病的临床效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年13期
页码:
97-99
栏目:
论著
出版日期:
2022-07-01

文章信息/Info

Title:
Clinical Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Ambroxol in the Treatment of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2022）13-0097-03
作者:
陈孝辉
（天津市宝坻区中医医院呼吸科，天津 301800）
Author(s):
CHEN Xiao-hui
(Department of Respiratory,Baodi District Hospital of Traditional Chinese Medicine,Tianjin 301800,China)
关键词:
哌拉西林钠他唑巴坦钠; 氨溴索; 慢性阻塞性肺疾病; 肺功能
Keywords:
Piperacillin sodium and tazobactam sodium; Ambroxol; Chronic obstructive pulmonary disease; Lung function
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2022.13.021
文献标志码:
A
摘要:
目的 研究哌拉西林钠他唑巴坦钠+氨溴索治疗慢性阻塞性肺疾病的临床效果。方法 选取2018年9月-2021年7月在我院治疗的82例慢性阻塞性肺疾病患者为研究对象，采用随机数字表法分为对照组和观察组，各41例。对照组采用氨溴索治疗，观察组在对照组基础上联合哌拉西林钠他唑巴坦钠治疗，比较两组临床效果、肺功能指标、降钙素原（PCT）、C反应蛋白（CRP）水平及不良反应发生情况。结果 观察组治疗总有效率为92.68%，高于对照组的82.93%，差异有统计学意义（P＜0.05）；两组呼气峰流速（PEF）、第1秒用力呼气容积（FEV1）、用力肺活量（FVC）均高于治疗前，且观察组高于对照组，差异有统计学意义（P＜0.05）；两组PCT、CRP水平均低于对照组，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为2.44%，低于对照组的14.63%，差异有统计学意义（P＜0.05）。结论 哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病效果显著，可提高治疗效果，改善患者肺功能指标，减轻血清炎症因子水平，不良反应少，是一种安全、有效的治疗方案。
Abstract:
Objective To study the clinical effect of piperacillin sodium and tazobactam sodium+ambroxol in the treatment of chronic obstructive pulmonary disease.Methods A total of 82 patients with chronic obstructive pulmonary disease treated in our hospital from September 2018 to July 2021 were selected as the research subjects. They were divided into control group and observation group by random number table method, with 41 cases in each group. The control group was treated with ambroxol, and the observation group was treated with piperacillin sodium and tazobactam sodium on the basis of the control group. The clinical effect, pulmonary function indexes, procalcitonin (PCT), C-reactive protein (CRP) levels and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 92.68%, which was higher than 82.93% of the control group, and the difference was statistically significant (P<0.05). The peak expiratory flow (PEF), forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) of the two groups were higher than those before treatment, and those in the observation group was higher than those in the control group, the difference was statistically significant (P<0.05). The levels of PCT and CRP in the two groups were lower than those in the control group, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 2.44%, which was lower than 14.63% in the control group, and the difference was statistically significant (P<0.05).Conclusion Piperacillin sodium and tazobactam sodium combined with ambroxol is effective in the treatment of chronic obstructive pulmonary disease, which can improve the therapeutic effect, improve the pulmonary function index of patients, reduce the level of serum inflammatory factors, and has less adverse reactions. It is a safe and effective treatment scheme.

参考文献/References:

[1]武红莉,田瑞雪,宁兰丁,等.慢性阻塞性肺疾病患者肺部感染的影响因素分析及血清炎症因子水平变化分析[J].中华医院感染学杂志,2018,28(1):25-28.[2]陈好权,孙云华.自拟活血化痰方联合抗生素治疗慢性阻塞性肺疾病伴肺部感染的效果观察[J].中国中医药科技,2018,25(4):533-534.[3]宋玉龙,侯伟,金茜.慢性阻塞性肺疾病患者急性加重期合并肺部感染的病原菌分布及危险因素分析[J].工业卫生与职业病,2019,45(3):227-228,231.[4]徐英.肺部感染对慢阻肺急性加重期患者外周血淋巴细胞免疫分型的影响[J].临床肺科杂志,2018,23(8):1450-1454.[5]中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性阻塞性肺疾病基层诊疗指南(2018 年)[J].中华全科医师杂志,2018,17(11): 856-87.[6]王云霞,宓文珍,赵丽丽,等.盐酸氨溴索应用剂量对COPD呼吸机相关肺部感染患者临床效果的影响[J].中华医院感染学杂志,2018,28(9):1338-1341.[7]蔡海彬,刘国雄,谢坚,等.盐酸氨溴索治疗慢性阻塞性肺疾病伴肺部感染的疗效观察[J].西北药学杂志,2018,33(1):113-116.[8]候诚,李秀红,王镇.布地奈德联合盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病急性加重期的效果分析[J].中国基层医药,2018,25(12):1514-1517.[9]卞庆平.噻托溴铵联合舒利迭对中重度COPD 患者炎症因子、血气指标及肺功能的影响[J].临床肺科杂志,2019,24(1):58-60.[10]梁蔚繁.盐酸氨溴索联合噻托溴铵治疗急性期老年慢性阻塞性肺疾病的临床效果[J].中国医药,2020,15(6):864-868.[11]龙瀛,胡建平,何正光,等.盐酸氨溴索对慢性阻塞性肺疾病患者免疫功能及炎症因子的影响[J].现代生物医学进展,2018,18(18):3538-3541,3567.[12]翟静,李向欣,赵鹏程.人免疫球蛋白联合哌拉西林钠他唑巴坦钠治疗重症肺部感染的临床研究[J].现代药物与临床,2018,33(8):1954-1959.[13]刘新美,吴晶,刘丹萍,等.异丙托溴铵、布地奈德、博利康尼联合雾化吸入对慢性阻塞性肺疾病加重期的疗效观察[J].中华肺部疾病杂志,2016,9(6):640-642.[14]邹菊香.布地奈德对慢性阻塞性肺疾病急性加重期患者IL-8、CRP水平及生活质量的影响[J].中华保健医学杂志,2017,19(4):313-315.[15]于季红,闫中强,赵秀梅,等.阿米卡星联合哌拉西林他唑巴坦钠治疗老年重症肺炎的临床疗效[J].中华医院感染学杂志,2020,30(18):2759-2763.[16]刘丽萍.溴己新联合哌拉西林钠他唑巴坦钠治疗慢性支气管炎急性发作63 例[J].疾病监测与控制,2016,10(2):152-153.[17]潘小娟.哌拉西林/他唑巴坦治疗社区获得性肺炎的临床疗效分析[J].中国基层医药,2018,25(12):1501-1505.[18]林色永.哌拉西林钠他唑巴坦钠联合痰热清治疗老年肺气肿合并感染的临床疗效[J].深圳中西医结合杂志,2017,27(15):137-138.[19]杨静.哌拉西林钠他唑巴坦联合盐酸氨溴索治疗老年急性肺炎的临床观察[J].中国卫生标准管理,2016,7(5):112-113.[20]李荣辉,郭小兰,刘湘,等.哌拉西林钠他唑巴坦钠不良反应72 例临床分析[J].中国现代医药杂志,2019,21(1):81-82.

相似文献/References:

[1]史贻芳.普米克令舒联合氨溴索治疗新生儿肺炎的临床疗效观察[J].医学信息,2018,31(04):132.[doi:10.3969/j.issn.1006-1959.2018.04.047]
　SHI Yi-fang.Clinical Effect of Pulmicort Combined with Ambroxol in the Treatment of Neonatal Pneumonia[J].Medical Information,2018,31(13):132.[doi:10.3969/j.issn.1006-1959.2018.04.047]
[2]刘成丽.氨溴索在哮喘性支气管炎治疗中的应用效果及安全性评价[J].医学信息,2018,31(05):138.[doi:10.3969/j.issn.1006-1959.2018.05.049]
　LIU Cheng-li.Efficacy and Safety Evaluation of Ambroxol in the Treatment of Asthmatic Bronchitis[J].Medical Information,2018,31(13):138.[doi:10.3969/j.issn.1006-1959.2018.05.049]
[3]罗玉霞.舒适护理在布地奈德联合氨溴索雾化吸入治疗 慢阻肺急性发作患者的效果分析[J].医学信息,2018,31(12):179.[doi:10.3969/j.issn.1006-1959.2018.12.058]
　LUO Yu-xia.Analysis of the Effect of Comfortable Nursing in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients with Aerosolized Inhalation of Budesonide and Ambroxol[J].Medical Information,2018,31(13):179.[doi:10.3969/j.issn.1006-1959.2018.12.058]
[4]曾文宏,叶芳芳,周志明.哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗慢性支气管炎的临床疗效及安全性观察[J].医学信息,2022,35(23):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
　ZENG Wen-hong,YE Fang-fang,ZHOU Zhi-ming.Observation on Clinical Efficacy and Safety of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin in the Treatment of Chronic Bronchitis[J].Medical Information,2022,35(13):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
[5]叶芳芳,周志明,曾文宏.哌拉西林钠他唑巴坦钠联合左氧氟沙星对支气管扩张患者气道功能、炎症反应的影响[J].医学信息,2023,36(01):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]
　YE Fang-fang,ZHOU Zhi-ming,ZENG Wen-hong.Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin on Airway Function and Inflammatory Response in Patients with Bronchiectasis[J].Medical Information,2023,36(13):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]
[6]刘斌先.布地奈德、沙丁胺醇雾化吸入联合氨溴索注射液治疗小儿支气管肺炎的效果及对WBC、CRP的影响[J].医学信息,2024,37(02):136.[doi:10.3969/j.issn.1006-1959.2024.02.027]
　LIU Bin-xian.Clinical Effect of Budesonide and Salbutamol Aerosol Inhalation Combined with Ambroxol Injection in the Treatment of Bronchial Pneumonia in Children and its Effect on WBC and CRP[J].Medical Information,2024,37(13):136.[doi:10.3969/j.issn.1006-1959.2024.02.027]
[7]彭水华,杨智文,廖乙媚,等.哌拉西林钠他唑巴坦钠相关腹泻的临床特征分析[J].医学信息,2024,37(04):61.[doi:10.3969/j.issn.1006-1959.2024.04.010]
　PENG Shui-hua,YANG Zhi-wen,LIAO Yi-mei,et al.Analysis of Clinical Characteristics of Diarrhea Caused by Piperacillin/Tazobactam[J].Medical Information,2024,37(13):61.[doi:10.3969/j.issn.1006-1959.2024.04.010]

更新日期/Last Update: 1900-01-01